PTO

A

C Marie Bease type a plus sign (+) Inside this box → PTO/SB/05 (2/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.		PC10616ATMC		
First Named	I Inventor or Applic	ation Identifier	David B. MacLean	
Title	Intermittent Adm	rmittent Administration of a Growth Hormone Secretagogue		
Eynress Mail I ahel No		FI 01172	EL 911724340LIS	

101117 101 110117 1	onprovisional applications under 37C.r.n. §1 33(b))				
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.			ASSISTANT Commissioner for Patents Box Patent Application Washington, DC 20231		
1.	*Fee Transmittal Form (e.g., PTO/SB/17) Submit an original, and a duplicate for fee processing)	6.			
2.	Specification [Total Pages 76] (preferred arrangement set forth below)] 7.	7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)		
	Descriptive title of the Invention Cross References to Related Applications Statement Regarding Fed sponsored R&D		a. Computer Readable Copy b. Paper Copy (identical to computer copy)		
	- Reference in Microfiche Appendix		c. Statement verifying identity of above copies		
- Background of the Invention			ACCOMPANYING APPLICATION PARTS		
	 Brief Summary of the Invention Brief Description of the Drawings (if filed) 	8.	8. Assignment Papers (cover sheet & document(s))		
}	 Detailed Description Claim(s) Abstract of the Disclosure 	9.	9 37 C.F.R §3.73(b) Statement Power of Attorney (when there is an assignee)		
	- Abstract of the Disclosure	10	10. English Translation Document (if applicable)		
	Drawing(s) (35 U.S.C. 11.3)[Total sheets	1 1	11. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations		
4.	Oath or Declaration [Total pages	1 12	12. Preliminary Amendment		
	Newly executed (original or copy) Copy from a prior application (37 CFR	10	13. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)		
	§1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below]	14	14. *Small Entity Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)		
	i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).	15	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)		
5.	Incorporation By Reference (useable if Box 4b is checke	a) 16	16. Other: Priority Claim		
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.			This application claims priority of U.S. provisional application number 60/229,077, filed August 30, 2000.		
"NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).					
17. If a C	CONTINUING APPLICATION, check appropriate box, and	supply	ly the requisite information below and in a preliminary amendment:		
Continuation Divisional Continuation-in-part (CIP) of prior application No:/					
Prior application information: Examiner Group/Art Unit:					
18. CORRESPONDENCE ADDRESS					
Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or Correspondence address below					
Name	Gregg C. Benson				
Address	Pfizer Inc.				
Address Patent Department, MS 4159, Eastern Point Road					
City Groton State			CT Zip Code 06340		
Country	United States Of America Telephone		1-(860)-441-4901		
NAME (Print/type) Todd M. Crissey Registration No. (Attorney/Agent) 37,807					
	ature July 91		Date & [27 /204]		

PTO/SB/17(2/98) Approved for use through 09/30/2000. U.S. DEPARTMENT OF COMMERCE

OMB 0651-0032 Patent and Trademark Office: Complete if Known Application Number To be assigned FEE TRANSMITTAL Concurrently Herewith Filing Date David B. MacLean Patent fees are subject to annual revision on October 1. First Named Inventor These are the fees effective October 1,. 2000. Examiner Name Small Entity payments must be supported by a small entity statement, To be assigned otherwise large entity fees must be paid. See Forms PTO/SB/09-12. Group/Art Unit To be assigned See 37 C.F.R. §§ 1 27 and 1.28 **Total Amount of Payment** (\$)890.00 Attorney Docket No. PC10616ATMC METHOD OF PAYMENT (check one) FEE CALCULATION (continued) The commissioner is hereby authorized to charge 3. ADDITIONAL FEES Large Entity **Small Entity** indicated fees and credit any over payments to: Deposit Account 16-1445 Code (\$) Code (\$) Fee Description Fee Paid Number Deposit 205 65 Surcharge - late fee or oath 105 130 Account Name Pfizer Inc 25 Surcharge-late provisional filing fee or 127 50 227 cover sheet Charge Any Additional Charge the Issue Fee Set in 37 Fee Required Under 37 C.F.R. § 1.1.8 at the Mailing 139 130 139 130 Non-English specification C.F.R. §§ 1.1 6 and 1.17. of the Notice of Allowance. 147 2.520 147 2,520 For filing a request for reexamination 112 920* 112 920* Requesting publication of SIR prior to 2. Payment Enclosed: Examiner action 1,840* 1,840* Requesting publication of SIR after 113 113 ☐ Other ☐ Check ☐ Money Order Examiner action FEE CALCULATION 115 110 215 55 Extension for reply within first month BASIC FILING FEE 116 390 216 195 Extension for reply within second 117 890 217 445 Extension for reply within third month Large Entity Small Entity Fee Description Fee Paid 1,390 218 695 Extension for reply within fourth month 118 Ćode (\$) Code (\$) 128 1,890 228 945 Extension for reply within fifth month 101 710 201 355 Utility filing fee 710.00 119 310 219 155 Notice of Appeal ₌106 320 206 160 Design filma fee 107 120 310 220 155 Filing a brief in support of an appeal 490 207 245 Plant filing fee).08 121 270 221 135 Request for oral hearing 710 208 355 Reissue filing fee 138 1,510 138 1.510 Petition to institute a public use 150 Provisional filing fee 1,14 214 75 proceeding 77 710.00 140 SUBTOTAL (1) (\$) 110 240 55 Petition to revive - unavoidable 2. EXTRA CLAIM FEES 141 1,240 241 620 Petition to revive - unintentional Extra Fee from 142 1,240 242 620 Utility issue fee (or reissue) Fee Paid Claims below Total Claims 30 180.00 -20**≈ 10 18.00 143 440 243 220 Design issue fee 600 244 300 Plant issue fee 144 Independent 3 80 00 0.00 130 122 130 Petitions to the Commissioner 122 Multiple Dependent 270.00 ** or number previously paid, if greater; For Reissues, see below 123 50 123 50 Petitions related to provisional **Small Entity** Large Entity applications Fee Fee Fee Fee Fee Description 126 240 126 240 Submission of Information Disclosure Code (\$) Code (\$) Statement 103 18 203 Claims in excess of 20 581 40 581 40 Recording each patent assignment per 9 property (times number of properties) 102 80 202 40 Independent claims in excess of 3 146 710 246 355 Filing a submission after final rejection (37 CFR 1.129(a)) 104 270 204 135 Multiple dependent claim, if not paid 710 149 249 355 For each additional invention to be examined (37 CFR 1.129(b)) **Reissue independent claims over 109 80 209 40 Other Fee (specify) original patent 110 18 210 **Reissue claims in excess of 20 and Other Fee (specify) over original patent SUBTOTAL (2) (\$) *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0.00 180 00 SUBMITTED BY Complete (if Applicable) Type or Printed Name Reg. Number 37.807 Signature Date Deposit Account 16-1445 8/27/ 200 User ID

100